IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Preparations Underway for Phase 3 Ovarian Cancer Trial; Set to Initiate in 1Q25 Imunon, Inc. (NASDAQ:IMNN) previously reported positive topline ...

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the ...

The company first kicked off its OASIS trials in October last year at the City of Hope’s NCI-designated comprehensive cancer ...

To reduce colorectal cancer risk, being active in both the early morning and evening might provide greater benefits than ...

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., ...

The addition of nivolumab to rucaparib maintenance therapy did not improve progression-free survival (PFS) in patients with ovarian cancer, outcomes of the phase 3 ATHENA-COMBO trial demonstrated. In ...

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

According to the National Cancer Institute, the primary aim of palliative surgery is to “reduce pain and/or other symptoms” ...

Our mission is to broaden the potential, and reach, of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational ...

She remembers her first MAID patient, who had ovarian cancer. Richmond had many conversations with her, asking whether she truly wanted to go through with the process. The patient insisted that she ...

Fewer and fewer twins and triplets are being born through IVF in Australia, bringing IVF and overall Australian multiple ...